Document Detail


Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
MedLine Citation:
PMID:  22741814     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Introduction: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. Areas covered: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. Expert opinion: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.
Authors:
Petra Dunkel; Christina Ll Chai; Beáta Sperlágh; Paul B Huleatt; Péter Mátyus
Related Documents :
9247914 - Relationship of dehydroepiandrosterone and cortisol in disease.
20559954 - Approaching biomarker discovery through genomics.
20425434 - New and old prognostic factors in polycythemia vera.
17654004 - Work-ability evaluation: a piece of cake or a hard nut to crack?
24171844 - Mycobacterium bovis: characteristics of wildlife reservoir hosts.
22644374 - Valvular heart disease in circulation and the circulation subspecialty journals.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-28
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  -     ISSN:  1744-7658     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Semmelweis University, Department of Organic Chemistry , Hőgyes Endre utca 7, 1094 Budapest , Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unintentional injury mortality in India, 2005: nationally representative mortality survey of 1.1 mil...
Next Document:  Reliability of Indicators of Decline in Abundance.